FDA Approved: QBREXZA — Original Application (Journey Medical Corporation)

View source ↗

Summary

FDA approved QBREXZA (glycopyrronium) from Journey Medical Corporation as an original NDA for the topical treatment of primary axillary hyperhidrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axillary Hyperhidrosis

Drugs mentioned

• Qbrexza (glycopyrronium tosylate)

Snippet

ORIG AP for QBREXZA (GLYCOPYRRONIUM)